Greene, Kaitlin A.
Lu, Vivien
Luciano, Marta San
Qubty, William
Irwin, Samantha L.
Grimes, Barbara
Gelfand, Amy A.
Article History
Received: 14 July 2020
Revised: 17 November 2020
Accepted: 18 November 2020
First Online: 9 February 2021
Competing interests
: M.S.L. has received consulting fees from Boston Scientific in 2019; receives grant support from NIH (NINDS, K23NS0099441-O1A), and receives personal compensation for medico-legal consulting. A.A.G. has received consulting fees from Theranica, Advanced Clinical, Biohaven, Impel Neuropharma, and Satsuma; has received honoraria from <i>UpToDate</i> (for authorship) and <i>JAMA Neurology</i> (as an associate editor); receives grant support from Amgen and the Duke Clinical Research Institute; has received personal compensation for medical–legal consulting (last in Jan 2019); her spouse reports research support (to UCSF) from Genentech for a clinical trial, honoraria for editorial work from Dynamed Plus, and personal compensation for medical–legal consulting. S.L.I. receives honoraria for authoring a chapter for the Canadian Pharmacy Association (CPhA) and research support from the Duke Clinical Research Institute. The remaining authors (K.A.G., V.L., W.Q., B.G.) have nothing to disclose.
: All subjects provided written informed consent. Children aged 7–17 years provided assent, and those who had reached the age of 18 years provided consent for their parent/caregiver to be interviewed about their history of BPT. Families provided consent for use of photographs/videos for publication.